MA40110B2 - Dérivés de 7-(morpholinyl)-2-(n-pipérazinyl)méthylthiéno[2, 3-c]pyridine en tant que médicaments anticancéreux - Google Patents

Dérivés de 7-(morpholinyl)-2-(n-pipérazinyl)méthylthiéno[2, 3-c]pyridine en tant que médicaments anticancéreux

Info

Publication number
MA40110B2
MA40110B2 MA40110A MA40110A MA40110B2 MA 40110 B2 MA40110 B2 MA 40110B2 MA 40110 A MA40110 A MA 40110A MA 40110 A MA40110 A MA 40110A MA 40110 B2 MA40110 B2 MA 40110B2
Authority
MA
Morocco
Prior art keywords
methylthieno
piperazinyl
morpholinyl
pyridine derivatives
anticancer drugs
Prior art date
Application number
MA40110A
Other languages
English (en)
Other versions
MA40110A1 (fr
Inventor
Kali Satya Bhujanga Rao Adibhatla
Venkaiah Chowdary Nannapaneni
Durga Prasad Konakanchi
Subba Rao Pula
Rama Krishna Pilli
Lakshmana Viswa Venkata Pavan Kumar Maddula
Srinivasa Krishna Murthy Konduri
Janaki Rama Rao Ravi
Naga Vasanta Srinivasu Vuppalapati
Sandeep Kumar Thoota
Pulla Reddy Muddasani
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of MA40110A1 publication Critical patent/MA40110A1/fr
Publication of MA40110B2 publication Critical patent/MA40110B2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une nouvelle série de dérivés de 7-(morpholinyl)-2-(n-pipérazinyle)-méthylthiéno[2, 3-c]pyridines substitués représentés par la formule i dans laquelle r1, r2, r3 et r4 sont tels que définis dans la description.
MA40110A 2014-12-11 2014-12-11 Dérivés de 7-(morpholinyl)-2-(n-pipérazinyl)méthylthiéno[2, 3-c]pyridine en tant que médicaments anticancéreux MA40110B2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2014/000770 WO2016092556A1 (fr) 2014-12-11 2014-12-11 Dérivés de 7-(morpholinyl)-2-(n-pipérazinyl)méthylthiéno[2, 3-c]pyridine en tant que médicaments anticancéreux

Publications (2)

Publication Number Publication Date
MA40110A1 MA40110A1 (fr) 2017-12-29
MA40110B2 true MA40110B2 (fr) 2020-12-31

Family

ID=52595387

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40110A MA40110B2 (fr) 2014-12-11 2014-12-11 Dérivés de 7-(morpholinyl)-2-(n-pipérazinyl)méthylthiéno[2, 3-c]pyridine en tant que médicaments anticancéreux

Country Status (32)

Country Link
US (1) US10106554B2 (fr)
EP (1) EP3230289B1 (fr)
JP (1) JP6454419B2 (fr)
KR (1) KR102328921B1 (fr)
CN (1) CN107074873B (fr)
AP (1) AP2017009749A0 (fr)
AU (1) AU2014413483B2 (fr)
BR (1) BR112017005518B1 (fr)
CA (1) CA2959980C (fr)
CO (1) CO2017002266A2 (fr)
CY (1) CY1122080T1 (fr)
DK (1) DK3230289T3 (fr)
EA (1) EA036819B1 (fr)
ES (1) ES2750268T3 (fr)
HR (1) HRP20192041T1 (fr)
HU (1) HUE047144T2 (fr)
IL (1) IL252254B (fr)
LT (1) LT3230289T (fr)
MA (1) MA40110B2 (fr)
MX (1) MX2017004782A (fr)
MY (1) MY188946A (fr)
NZ (1) NZ729078A (fr)
PH (1) PH12017500342B1 (fr)
PL (1) PL3230289T3 (fr)
PT (1) PT3230289T (fr)
RS (1) RS59409B1 (fr)
SG (1) SG11201702162PA (fr)
SI (1) SI3230289T1 (fr)
SM (1) SMT201900622T1 (fr)
UA (1) UA117318C2 (fr)
WO (1) WO2016092556A1 (fr)
ZA (1) ZA201701036B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3150681A1 (fr) 2019-08-14 2021-02-18 Incyte Corporation Composes imidazolyl-pyrimidinylamines utilises comme inhibiteurs de la cdk2
US11851426B2 (en) * 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN118496197A (zh) 2019-12-20 2024-08-16 拜耳公司 取代的噻吩甲酰胺、噻吩甲酸及其衍生物
WO2022224267A1 (fr) * 2021-04-21 2022-10-27 Natco Pharma Limited Procédé amélioré pour la préparation de dérivés de 7-(morpholinyl)-2-(n-pipérazinyl)méthylthiéno[2, 3-c]pyridine
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579526A (en) 1968-11-13 1971-05-18 Research Corp Preparation of thienopyridines
FR2411838A1 (fr) 1977-12-19 1979-07-13 Parcor Nouveaux derives des thieno (2-3-c) et (3,2-c) pyridines, leurs procede de preparation et leur application therapeutique
US4839365A (en) 1987-05-19 1989-06-13 Shinogi & Co., Ltd. Thienopyridine derivatives useful in treating gastric ulcers
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
WO2000075145A1 (fr) 1999-06-03 2000-12-14 Abbott Laboratories Composes anti-inflammatoires inhibant l'adhesion cellulaire
WO2005110410A2 (fr) 2004-05-14 2005-11-24 Abbott Laboratories Inhibiteurs de kinases en tant qu'agents therapeutiques
GB0608264D0 (en) * 2006-04-26 2006-06-07 Piramed Ltd Pharmaceutical compounds
KR20090021155A (ko) * 2006-04-26 2009-02-27 에프. 호프만-라 로슈 아게 Ｐｉ3ｋ 억제제로서의 피리미딘 유도체
EP2205242B1 (fr) * 2007-09-12 2015-04-15 Genentech, Inc. Combinaisons de composés inhibiteurs des phosphoinositide 3-kinases et agents chimiothérapeutiques, et leurs procédés d'utilisation
GB0723748D0 (en) 2007-12-04 2008-01-16 Ucb Pharma Sa Therapeutic agents
MX2010010659A (es) 2008-03-31 2010-10-26 Genentech Inc Compuestos de benzopirano y benzoxepina, inhibidores de fosfoinoinositida 3-cinasas y metodos para utilizarlos.
EA024252B1 (ru) * 2009-01-08 2016-08-31 Кьюрис, Инк. Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой
JP2013505965A (ja) 2009-09-29 2013-02-21 エックスカバリー ホールディング カンパニー エルエルシー Ｐｉ３ｋ（デルタ）選択的阻害剤
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
RU2013138835A (ru) * 2011-02-09 2015-03-20 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения в качестве ингибиторов pi3 киназы

Also Published As

Publication number Publication date
MX2017004782A (es) 2017-07-27
CY1122080T1 (el) 2020-11-25
EA201791294A1 (ru) 2017-11-30
IL252254A0 (en) 2017-07-31
HRP20192041T1 (hr) 2020-02-07
RS59409B1 (sr) 2019-11-29
ES2750268T3 (es) 2020-03-25
SI3230289T1 (sl) 2019-10-30
JP6454419B2 (ja) 2019-01-16
UA117318C2 (uk) 2018-07-10
PH12017500342A1 (en) 2017-07-17
PL3230289T3 (pl) 2020-03-31
CA2959980C (fr) 2023-04-25
CN107074873B (zh) 2022-01-07
KR102328921B1 (ko) 2021-11-19
DK3230289T3 (da) 2019-10-28
US10106554B2 (en) 2018-10-23
BR112017005518B1 (pt) 2022-11-29
WO2016092556A1 (fr) 2016-06-16
CN107074873A (zh) 2017-08-18
HUE047144T2 (hu) 2020-04-28
MA40110A1 (fr) 2017-12-29
SG11201702162PA (en) 2017-04-27
CO2017002266A2 (es) 2017-05-31
MY188946A (en) 2022-01-14
EA036819B1 (ru) 2020-12-23
AP2017009749A0 (en) 2017-02-28
BR112017005518A2 (pt) 2017-12-05
SMT201900622T1 (it) 2020-01-14
ZA201701036B (en) 2019-06-26
AU2014413483B2 (en) 2019-07-25
PT3230289T (pt) 2019-10-30
CA2959980A1 (fr) 2016-06-16
EP3230289B1 (fr) 2019-08-14
JP2017537139A (ja) 2017-12-14
EP3230289A1 (fr) 2017-10-18
NZ729078A (en) 2021-07-30
LT3230289T (lt) 2019-10-10
PH12017500342B1 (en) 2023-03-17
AU2014413483A1 (en) 2017-03-09
KR20170090434A (ko) 2017-08-07
IL252254B (en) 2019-08-29
US20170320891A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
JO3807B1 (ar) مشتقات حمض هيدروكسي جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
MX380122B (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
MA39317A1 (fr) Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe
MX2019004578A (es) Oxisteroles y metodos de uso de los mismos.
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
EA201892838A1 (ru) Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
EA201890125A1 (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
UA117958C2 (uk) Похідні хіноксаліну, корисні як модулятори кінази fgfr
MA40110B2 (fr) Dérivés de 7-(morpholinyl)-2-(n-pipérazinyl)méthylthiéno[2, 3-c]pyridine en tant que médicaments anticancéreux
EA201692003A1 (ru) Макроциклические производные пиримидина
PH12019501178A1 (en) Thiopene derivatives as antiviral agents
MX375099B (es) Derivados de aminotiazol útiles como agentes antivíricos.
MX391221B (es) Compuestos y composiciones y usos de los mismos.
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
EA201790949A1 (ru) Замещенные 2,4-диаминохинолины в качестве новых противораковых средств
EA201790046A1 (ru) Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора
MA39171A1 (fr) Dérivés d'hydroxy formamide et leur utilisation
TR201819805T4 (tr) Flavaglin türevleri̇.
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA39374A1 (fr) Triterpénoïdes présentant une activité d'inhibition de la maturation du vih, substitués en 3ème position par un cycle non aromatique portant un substituant halogénoalkyle